E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with confirmed locally advanced or metastatic pancreatic adenocarcinoma treated by chemotherapy .
|
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10033610 |
E.1.2 | Term | Pancreatic carcinoma metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary objective: The aim of this prospective randomized controlled trial in patients with locally advanced or metastatic pancreatic cancer is to demonstare that Clopidogrel treatment can increase on Progression free Survival (PFS) at 6 months. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are to assess the impact of clopidogrel treatment on: -the occurrence venous thromboembolism events: Pulmonary embolism (PE), Lower Extremity DVT, Upper extremity DVT, Head/neck DVT, Visceral vein event. -the bleeding complications and safety of clopidogrel as measured by the rate of minor and major haemorrhages when used with chemotherapy and occasionally along with either curative (if onset of venous thrombo-embolism) or prophylactic dose of low molecular weight heparin as it can now be used in cancer patients for primary venous thromboembolism prophylaxis. -the overall response rate and overall survival. -the correlation between tumour regression / formation of metastasis and microparticules level before and after chemotherapy.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria - 18 years of age or older - Histologically and cytologically confirmed adenocarcinoma of the pancreas - Locally advanced or metastatic pancreatic adenocarcinoma - Measurable primary pancreatic cancer or metastasis - Pancreatic adenocarcinoma that has not previously been treated with chemotherapy either in an adjuvant or metastatic setting - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 - Adequate bone marrow: granulocyte count superior or equal to 1.5 G/L; and platelet count superior or equal to 100 G/L - Adequate liver function: bilirubin inferior or equal to 2 times the upper limit of the normal range, transaminases (AST and ALT) inferior or equal to 3 times the upper limit of the normal range - Adequate renal function: calculated clearance rate > 60 m.mn1 (Estimated glomerular filtration rate using Modification of Diet in Renal Disease (MDRD) formula or Cockcroft-Gault formula) - Women of childbearing potential must use an effective birth control method.
|
|
E.4 | Principal exclusion criteria |
Non-inclusion criteria - Endocrine or acinar pancreatic carcinoma - Pancreatic metastasis of other primary tumors - Previous radiotherapy for measurable lesions - Previous chemotherapy - History of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal disease - Other prior malignancy. Adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or any other cancer from which the patient has been disease free for > 5 years are allowed. - Known acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease requiring antiretroviral treatment. - Acute infection - Hemorrhagic diathesis - Aspirin with a daily dose > 75 mg - Curative dose of LMWH - Recent venous thromboembolism (1 year) - Patients under VKA - Lesion of the digestive tract that could be hemorrhagic with clopidogrel treatment - History of another major cancer except basal cell carcinoma of skin - Active infection - Chronic diarrhea - Clinically significant history of cardiac disease defined as a left ventricular ejection fraction below 45% - Pregnancy or breast-feeding - Hypersensitivity to clopidogrel or its excipients - Patients with severe hepatic impairment - Patients who are pregnant or breast feeding, or who are not using effective birth control methods - Participation in another clinical research protocol, participation in a trial of routine care is authorized at the same time as PANCREADOGREL - Patient under tutorship or curatorship - Patients unwilling or unable to comply with the protocol - Not affiliated to health system (bénéficiaire ou ayant droit)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary assessment criterion Progression-free survival covers the period when there is no evidence of disease progression. The diagnosis of progression disease by x-rays, computed tomography scans, magnetic resonance imaging or scans will be dated from the first positive record, even if determined in retrospect. The beginning of progression-free survival will be calculated starting from the time of inclusion.
Secondary assessment criteria - Venous thromboembolic events - Diagnosis of pulmonary embolism deep venous thrombosis and visceral vein event. - Bleedings( will be classified as major, clinically relevant non-major, trivial, or no bleeding). - Overall response rate Tumor response will be determined according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). - Overall survival Overall survival is defined as time from randomization to death from any cause. - Correlation between between tumour regression / formation of metastasis and microparticules level
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |